Women and Lung Cancer Research and Preventive Services Act of 2025
Summary
What This Bill Does
Requires HHS, in consultation with DOD and VA, to review and update federal lung-cancer research, prevention, diagnosis, treatment, screening, biomarker-testing, and public-awareness programs for women and populations with few known risk factors, then report findings and recommended program changes to congressional committees within 2 years.
Who Benefits and How
Women with lung cancer benefit because HHS must identify knowledge gaps, environmental and genomic factors, and treatment or diagnostic research needs specific to women. Populations with few known risk factors benefit because the review must focus on improving outcomes and USPSTF-recommended screening rates. Lung cancer screening programs benefit from federal review of public-health strategies, biomarker testing, risk assessment, diagnosis, and evidence-based education. Federally funded researchers benefit from clearer interagency research priorities across HHS, DOD, and VA.
Who Bears the Burden and How
HHS cancer program staff must review ongoing research, strategic plans, public-health strategies, screening rates, biomarker testing, and program changes. DOD medical research staff and VA research staff must consult on service-member and veteran research overlaps. Federal agency heads may need to alter programs, activities, or strategic plans based on the review. Congressional committees must evaluate the 2-year report, barriers, and recommended statutory or program changes.
Key Provisions
- Requires HHS to review and update federal programs on lung cancer research, prevention, diagnosis, and treatment.
- Directs the review to identify knowledge gaps and improve outcomes for women and populations with few known risk factors.
- Requires consideration of environmental factors, genomic factors, screening rates, biomarker testing, technology, interventions, and public education.
- Requires consultation with DOD and VA.
- Requires a report to Senate HELP, Senate Appropriations, House Energy and Commerce, and House Appropriations within 2 years.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Requires HHS, in consultation with DOD and VA, to review and update federal lung-cancer research, prevention, diagnosis, treatment, screening, biomarker-testing, and public-awareness programs for women and populations with few known risk factors, then report findings and recommended program changes to congressional committees within 2 years.
Key Policy Areas
Cancer Research, Public Health, Women's Health, Veterans Health
Primary Purpose
Requires HHS, in consultation with DOD and VA, to review and update federal lung-cancer research, prevention, diagnosis, treatment, screening, biomarker-testing, and public-awareness programs for women and populations with few known risk factors, then report findings and recommended program changes to congressional committees within 2 years.
Policy Domains
House resolution provisions
Identified Gains
- Women with lung cancer benefit because HHS must identify knowledge gaps, environmental and genomic factors, and treatment or diagnostic research needs specific to women
- Populations with few known risk factors benefit because the review must focus on improving outcomes and USPSTF-recommended screening rates
- Lung cancer screening programs benefit from federal review of public-health strategies, biomarker testing, risk assessment, diagnosis, and evidence-based education
- Federally funded researchers benefit from clearer interagency research priorities across HHS, DOD, and VA
Identified Costs
- HHS cancer program staff must review ongoing research, strategic plans, public-health strategies, screening rates, biomarker testing, and program changes
- DOD medical research staff and VA research staff must consult on service-member and veteran research overlaps
- Federal agency heads may need to alter programs, activities, or strategic plans based on the review
- Congressional committees must evaluate the 2-year report, barriers, and recommended statutory or program changes
Sponsors
Legislative Progress
Passed SenateHeld at the desk.
Received in the House.
Message on Senate action sent to the House.
Passed/agreed to in Senate: Passed Senate with an amendment by …
Passed Senate with an amendment by Unanimous Consent. (consideration: CR …
Committee on Health, Education, Labor, and Pensions. Reported by Senator …
Reported by Mr. Cassidy, with an amendment
Placed on Senate Legislative Calendar under General Orders. Calendar No. …
Committee on Health, Education, Labor, and Pensions. Ordered to be …
Read twice and referred to the Committee on Health, Education, …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
HHS cancer program staff, Underserved screening populations
Positive-direction: Underserved screening populations
Negative-direction: HHS cancer program staff
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology